INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
MWN-AI** Summary
INVO Fertility, Inc. (Nasdaq: IVF) has announced a significant development in its proprietary INVOcell® device with the issuance of U.S. Patent No. 12,544,204 B2, effective February 10, 2026. This patent provides intellectual property protection for a modified version of the device through 2040. The INVOcell device, recognized as the world's first FDA-cleared intravaginal culture (IVC) system, offers a more natural and patient-centered alternative to traditional in vitro fertilization (IVF) by allowing fertilization and early embryo development to occur within a woman’s body.
Originally granted FDA clearance in 2015, INVOcell received an update in 2023 which extended the recommended incubation period from three to five days. This enhancement was driven by clinician feedback and real-world use, leading to a simplified design featuring a single main chamber, omitting the previously existing microchamber.
CEO Steve Shum highlighted the patent's issuance as a vital milestone in strengthening the intellectual property underpinnings of the INVOcell platform. By enabling fertilization within the patient rather than in a laboratory, INVOcell presents a novel approach that potentially delivers comparable outcomes to traditional IVF but at a more affordable price and with a more intimate experience for patients.
INVO Fertility aims to expand access to assisted reproductive technology (ART) care, operating two INVO Centers and an IVF clinic in the U.S., while also distributing the INVOcell device to third-party clinics. The company’s mission focuses on innovation in fertility treatment, seeking to improve patient experiences and outcomes in the evolving ART landscape. For more details, visit invofertility.com.
MWN-AI** Analysis
INVO Fertility, Inc. (Nasdaq: IVF) has recently strengthened its market position with the issuance of a U.S. patent for a modified version of its INVOcell® device, which could significantly enhance its competitive edge in the assisted reproductive technology (ART) sector. This patent not only secures the proprietary technology until 2040 but also highlights the company's commitment to innovation and quality in fertility care.
The INVOcell device stands out as an FDA-cleared intravaginal culture system, allowing fertilization and early embryo development to occur within the woman's body. This approach offers a more natural alternative to traditional IVF and aligns with contemporary patient-centered results. The simplified design of the modified device could enhance user experience, making ART procedures more accessible and potentially less invasive.
For investors, the implications of this patent issuance are substantial. First, it strengthens the company’s intellectual property portfolio, potentially increasing the valuation as the market recognizes its unique offerings. Furthermore, the expanded indication period for embryo incubation is likely to enhance clinical results, reinforcing the device's attractiveness to fertility clinics.
Given the rising demand for fertility services and innovations in reproductive technologies, INVO Fertility is well-positioned to capitalize on this growth. With only two operational clinics currently, a strategic expansion into new markets—both through additional clinic establishments and partnerships with existing fertility centers—could rapidly scale operations and revenues.
However, investors should remain aware of the inherent risks associated with stocks in the healthcare sector, especially those relying on technology and regulatory approvals. Continued diligence is recommended, focusing on clinical outcomes and financial health as the company progresses. Overall, INVO Fertility presents a promising opportunity in the fertility healthcare market, supported by a robust product with unique advantages.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040.
INVOcell is the world’s first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilization and early embryo development to take place within a woman’s body, offering a more natural and patient-centered alternative to traditional in vitro fertilization (IVF).
INVOcell was initially granted FDA clearance in 2015 and, in 2023, received additional FDA clearance for a labeling update that extended the recommended incubation period from three days to five days. The original INVOcell device design incorporated both a main chamber and a microchamber. Through years of real-world clinical use and feedback from practitioners, a simplified design featuring a single main chamber without a separate microchamber was designed. The Company subsequently submitted the modified design for patent protection which has now been granted.
“We are pleased to see our previously announced patent allowance conclude with this official issuance, which marks an important milestone for INVO Fertility as we continue to strengthen the intellectual property foundation around the INVOcell platform,” said Steve Shum, CEO of INVO Fertility. “INVOcell provides an additional treatment method in the fertility market, enabling fertilization and early embryo development to occur within the patient’s body rather than a traditional laboratory incubator. This expanded IP coverage supports our growth strategy and our mission to deliver high-quality fertility care through ongoing innovation.”
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding the Company’s ability to satisfy closing conditions for the offering, our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ**
How does the issuance of the U.S. patent for the modified INVOcell® device impact INVO Fertility Inc.'s competitive position in the IVF market?
What strategies does INVO Fertility Inc. plan to employ to expand its operational presence in the U.S. fertility clinics sector now that it holds a patent on the INVOcell device?
Can INVO Fertility Inc. provide details on the expected financial implications stemming from the patent for the INVOcell device in terms of revenue growth within the IVF segment?
How does the INVOcell device enhance the patient experience compared to traditional IVF methods, and what role does this play in INVO Fertility Inc.'s overall business strategy?
**MWN-AI FAQ is based on asking OpenAI questions about INVO Fertility Inc. (NASDAQ: IVF).
NASDAQ: IVF
IVF Trading
-7.77% G/L:
$0.5819 Last:
159,473 Volume:
$0.6125 Open:
